Fluzone High-Dose Quadrivalenta
AVAILABLE FOR THE 2020-2021 FLU SEASON
In a head-to-head randomized controlled trial, FLUZONE HIGH-DOSE VACCINE was proven to provide superior protection compared to Fluzone® (Influenza Vaccine).1,2
The occurrence of laboratory-confirmed, protocol-defined, influenza-like illness caused by viral strains regardless of their antigenic similarity to vaccine components.1,2
The occurrence of culture-confirmed influenza caused by viral types/subtypes antigenically similar to those contained in the respective annual vaccine formulations in association with a modified Centers for Disease Control and Prevention (CDC)–defined influenza-like illness.1,2
Fluzone High-Dose Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Fluzone High-Dose Quadrivalent is approved for use in persons 65 years of age and older.
Based on data from Fluzone High-Dose, solicited injection site reactions and systemic adverse reactions were slightly more frequent after vaccination with Fluzone High-Dose compared to a standard-dose vaccine.1
FLUZONE HIGH-DOSE: a selection of Demonstrated Real-WORLD Evidence from Every Year Since Launch3-7
a FDA = Food and Drug Administration. b CDC = Centers for Disease Control and Prevention. c CMS = Centers for Medicare and Medicaid Services.
a PERR = Previous event rate ratio.
a FFS = Fee-for-service.
Safety Profile of Fluzone High-Dose Quadrivalent is similar to Fluzone High-Dose Trivalent Formulation1
within 7 days of vaccination, RATES OF ANY SOLICITED local and systemic adverse reactions, as well as any grade 3 local and systemic adverse reactions, were similar among Fluzone High-Dose and Fluzone High-Dose Quadrivalent recipients.8
FLUZONE HIGH-DOSE QUADRIVALENT
- Helps to protect against 2 influenza A strains and BOTH INFLUENZA B LINEAGES that unpredictably co-circulate each season1
- 4X THE AMOUNT OF ANTIGEN of standard-dose quadrivalent inactivated influenza vaccine1
- 0.7-mL dose for intramuscular injection1
- Approved for use in adults 65+1
BASIS OF LICENSURE
Fluzone High-Dose Quadrivalent generated a similar immune response against influenza strains contained in trivalent formulations of Fluzone High-Dose, achieving non-inferiority criteria as assessed by Geometric Mean Titers (GMTs) and seroconversion rates.1
Fluzone High-Dose Quadrivalent induced a superior immune response to that of Fluzone High-Dose that did not contain the corresponding B strain, as assessed by HAI GMTs and seroconversion rates.1